[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Illinois at Chicago\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":634},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,128,0,25,[9,41,63,93,117,138,163,184,209,231,252,283,314,339,373,394,414,438,470,487,505,530,554,579,602],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100641343","phase-2-gi-05-the-impact-of-olanzapine-among-patients-receiving-neoadjuvant-chemotherapy-for-gastric-cancer-100641343",false,"NCT07581405","GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years of age at time of consent\n* Eastern Cooperative Oncology Group (ECOG) score of 0-2\n* Histologically confirmed gastric adenocarcinoma, documented by biopsy.\n* Planned to receive neoadjuvant chemotherapy followed by surgical resection, as determined by the treating oncologist.\n* Demonstrates adequate organ function. All screening labs are to be obtained within 30 days prior to registration.\n* Able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC Institutional Review Board informed consent form and HIPAA authorization. If a subject is unable to consent, a Legally Authorized Representative (LAR) may provide consent on their behalf.\n* Women of childbearing potential must not be pregnant or breastfeeding. A negative serum or urine pregnancy test is required per institutional practice guidelines.\n* As determined at the discretion of the enrolling physician or protocol designee, the ability of the subject to understand and comply with study procedures for the entire length of the study\n\nExclusion Criteria:\n\n* Active infection requiring systemic therapy\n* Uncontrolled HIV\u002FAIDS or active viral hepatitis\n* Pregnant or nursing\n* Any prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this investigational regimen, as determined by the treating medical oncologist.\n* Patients with a feeding tube (e.g., gastrostomy or jejunostomy) receive their primary source of nutritional intake via enteral tube feeding at the time of enrollment.\n* Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial.\n* Other major comorbidity, as determined by the study PI","ALL","18 Years",{"count":19,"type":20},26,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a single-center, randomized, open-label clinical trial designed to evaluate the impact of low-dose olanzapine on weight loss, appetite, and nutritional outcomes in patients with gastric cancer receiving neoadjuvant chemotherapy. Eligible patients will be randomized to receive olanzapine 2.5 mg orally once daily (QD) in addition to standard neoadjuvant chemotherapy, beginning prior to initiation of chemotherapy and continuing until surgical resection. Patients will otherwise receive standard-of-care (SOC) oncologic treatment, with no alterations to chemotherapy regimens or surgical management. The study is designed to prospectively assess whether olanzapine improves appetite, mitigates weight loss, and enhances nutritional status and quality of life (QoL) during neoadjuvant therapy. This study will be conducted at the University of Illinois Cancer Center (UICC) as a single-site investigator-initiated trial, with an anticipated accrual of 26 participants over 2 years.",[26,27],"Gastric Adenocarcinoma","Gastric Cancer","NOT_YET_RECRUITING","2026-08-19",{"date":31,"type":32},"2026-08-21","ACTUAL",{"date":34,"type":20},"2026-09",{"date":36,"type":20},"2030-09",{"name":38,"class":39},"University of Illinois at Chicago","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100550040","phase-2-bre-10-biomarker-optimization-of-neoadjuvant-therapy-in-breast-cancer-100550040","NCT06441890","BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer","BRE-10: BIomarker OptimizatioN of NeOadjuVAnt Therapy in BrEast Cancer: The INNOVATE Trial","BRE-10","Inclusion Criteria:\n\n* Age ≥ 18 years of age at time of consent\n* ECOG performance status 0, 1, or 2\n* Histologically confirmed invasive breast cancer documented by core needle or surgical biopsy with 90 days prior to study registration.\n* HER2-positive by IHC or FISH according to ASCO\u002FCAP 2018 guidelines\n* HER2-enriched subtype on the MammaPrint\u002FBluePrint gene expression profile within 90 days prior to study registration.\n* Curative resection of primary breast tumor(s) is planned; ipsilateral axillary nodes will be sampled by sentinel lymph node biopsy or axillary dissection\n* Treating Oncologist recommends neoadjuvant chemotherapy\n* No evidence of distant metastatic disease\n* AJCC clinical stage: cT1c-T3, cN0-N2\n* Baseline left ventricular ejection fraction (LVEF) of at least 50% on Echo or MUGA scan within 90 days prior to registration.\n\nAdequate organ function as defined below:\n\nLeukocytes ≥2,000\u002Fmm3 Platelet count ≥ 75,000\u002Fmm3 Absolute Neutrophil Count (ANC) ≥ 1,000\u002Fmm3 Hemoglobin (Hgb) ≥ 9.0 g\u002FdL Creatinine\u002FCalculated Creatine clearance (CrCI) Cr \\\u003C 1.5 x upper limit of normal (ULN) or CrCl ≥ 50 mL\u002Fmin using the Cockcroft-Gault formula Bilirubin ≤ 1.5 × ULN. Subjects with Gilbert's syndrome may have a bilirubin \\> 1.5 × ULN, if no evidence of biliary obstruction exists Aspartate aminotransferase (AST) ≤ 2.5 × ULN Alanine aminotransferase (ALT) ≤ 2.5 × ULN\n\n* Patients with synchronous bilateral primary breast tumors or multiple ipsilateral primary breast tumors are eligible if the treating Oncologist determines that the assigned treatment regimen is appropriate therapy for all primary tumors requiring chemotherapy.\n* Able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC Institutional Review Board (IRB) informed consent form and HIPAA authorization. or the Legally Authorized Representative (LAR) is able to provide consent and HIPAA authorization.\n* Women of childbearing potential must agree to use a barrier form of contraception if they are sexually active with a male partner and cannot be pregnant or breast-feeding. A negative serum or urine pregnancy test is required per institutional practice guidelines.\n* As determined at the discretion of the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.\n* Patients with history of HIV\u002FAIDS (acquired immunodeficiency syndrome) are eligible for this study if they are receiving anti-retroviral therapy and it does not include any medications known to alter metabolism or tolerability of component drugs in the protocol treatment regimen and the following criteria is met:\n\n  \\- Patients without a history of AIDS-defining opportunistic infections within the past 12 months.\n* Patients with Hepatitis B (HBV): chronic carriers of HBV infection (HBsAg-positive) or individuals who have serologic evidence of a resolved prior HBV infection (i.e., HBsAg-negative and anti-HBc-positive) are eligible if they are receiving appropriate suppressive antiviral therapy that does not include medications known to alter metabolism or tolerability of component drugs in the protocol treatment (see Appendix) prior to initiation of cancer therapy, and liver function tests meet study eligibility criteria.\n* Patients with Hepatitis C (HCV): patients with a history of HCV infection who have completed curative antiviral treatment are eligible if the HCV RNA viral load is below the limit of quantification within 90 days of study enrollment. Patients on concurrent HCV treatment must have HCV RNA viral load below the limit of quantification within 30 days of study enrollment. Patients must also meet liver function test eligibility requirements and antiviral therapy does not include medications known to alter metabolism or tolerability of component drugs in the protocol treatment\n\nExclusion Criteria\n\n* Any prior therapy for this breast cancer\n* Active infection requiring systemic therapy at the time of study registration\n* Pregnant or nursing\n* Any prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this investigational regimen, as determined by the treating medical oncologist.\n* Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial.\n* Other major comorbidity (e.g., compromised liver function, major cardiovascular or cerebrovascular event within the past 6 months, uncontrolled diabetes mellitus or hypertension), as determined by treating physician.\n* Any contraindication for any chemotherapy drug used in the assigned regimen.\n* Baseline sensory neuropathy \\> grade 1\n* History of hypersensitivity to any of the drugs in the treatment regimen. Patients with history of hypersensitivity may be treated on this protocol with either nab-paclitaxel or docetaxel.\n* Prisoners",{"count":50,"type":20},28,[23],"Adult men and women with early-stage, IHC\u002FFISH-defined HER2-positive breast cancer will have a MammaPrint®\u002FBluePrint® assay performed on the diagnostic biopsy specimen, ordered by the treating Oncologist as standard care",[54,55],"Breast Cancer","HER2-positive Breast Cancer","RECRUITING",{"date":31,"type":32},{"date":59,"type":32},"2024-12-05",{"date":61,"type":20},"2028-06",{"name":38,"class":39},{"id":64,"slug":65,"hasResults":12,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":16,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":40},"100605289","cognitive-motor-training-for-adadrd-prevention-100605289","NCT07160582","Cognitive-Motor Training for AD\u002FADRD Prevention","Innovative Cognitive-Motor Training for Prevention of AD\u002FADRD","Inclusion Criteria:\n\n1. Age: 55-90 years.\n2. No recent major surgery, bone fracture, or hospitalization (\\\u003C 3 months).\n3. Not on any sedative drugs.\n4. Can understand and communicate in English.\n5. Can walk without an assistive device for at least 1 block to ensure independent functioning.\n6. Identification of Mild Cognitive Impairment (MCI) based on Jak\u002FBondi criteria\n7. Visual acuity greater than or equal to 20\u002F40 with or without corrective lenses to ensure intact vision.\n\nExclusion Criteria:\n\n1. Participants will not proceed with the study if any of the following occurs at baseline measurement: 1) Heart Rate \\>85% of age-predicted maximal heart rate (HRmax) (HRmax = 220 - age), 2) systolic blood pressure (SBP) \\> 160 mmHg and\u002For diastolic blood pressure (DBP) \\> 110 mmHg during resting.\n2. Unable to stand for 5 minutes without an assistive device and walk for 10 m without an assistive device\n3. Complaints of shortness of breath, or uncontrolled pain (more than 3 out of 10 on Visual Analogue Scale), or if pulse oxygen drops less than 92% on the six-minute walk test (for endurance) to ensure that the participant can effectively participate without discomfort or injury during testing and training.\n4. Exhibits difficulty understanding the study information.\n5. Self-reported history or presence of any neurological, musculoskeletal, cardiorespiratory, or systemic disorders that significantly impact mobility or the ability to walk independently (without an assistive device).\n6. Self-reported disability (with or without an assistive device) to ensure independent functioning.\n7. Uncontrolled (not under any medications) hypertension to avoid cardiovascular complications during testing\u002Ftraining.\n8. Weight \\>220 lbs (harness weight threshold).",true,"55 Years","90 Years",{"count":74,"type":20},46,[76],"NA","Alzheimer's disease and related dementias (AD\u002FADRD) greatly affect memory and daily activities in older adults. Mild Cognitive Impairment (MCI) is an early stage of dementia, affecting about 17% of older adults. People with MCI often show problems with gait and balance, which doubles their risk of falling compared to cognitively healthy peers. Falls can cause injuries, increase sedentary behavior, and reduce physical activity. This decline in activity can also speed up the progression from MCI to dementia. Exercise can help older adults make healthy lifestyle changes; however, most of the existing exercise programs focus mainly on physical movement rather than cognitive function. Therefore, the investigators developed a new program that uses computer vision and a cloud-based system to provide more scalable, engaging, and personalized cognitive-motor training for OAwMCI. The purpose of this study is to investigate the short- and long-term effects of a novel CogXergaming training (CXT) paradigm for improving the cognitive-motor function, physical activity, falls efficacy, and quality of life.",[79,80],"MCI","Aging",[82,83,84],"CogXergaming","Cognitive-motor interference","Dual-task","2026-08-14",{"date":87,"type":32},"2026-08-18",{"date":89,"type":20},"2026-10-01",{"date":91,"type":20},"2027-12-01",{"name":38,"class":39},{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":12,"sex":16,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},"100564967","digital-integrated-behavioral-treatment-for-comorbid-obesity-and-depression-among-racial-and-ethnic-adults-age-50-and-older-100564967","NCT06636058","Digital InteGrated Behavioral treatmeNt for Comorbid obesITy and deprEssion Among Racial and Ethnic Adults Age 50 and Older","Digital InteGrated Behavioral treatmeNt for Comorbid obesITy and deprEssion Among Racial and Ethnic Adults Age 50 and Older (IGNITE)","IGNITE","Inclusion Criteria\n\n* Age 50-74 years (inclusive)\n* Confirmed body mass index (BMI) between ≥27.0 and \\\u003C45.0 based on weight and height measured by study staff at device distribution\n* Confirmed weight ≤396 lbs\n* Patient Health Questionnaire-9 (PHQ-9) scores between ≥10 and \\\u003C20, indicating moderate to moderately severe depressive symptoms\n* Self-identified race and ethnicity other than non-Hispanic White\n* Willing and able to accept randomization, and provide informed e-consent and HIPAA authorization\n\nExclusion Criteria\n\n* Unable to speak, read, understand English sufficiently for informed consent\n* No reliable Wi-Fi Internet access at home\n* Pre-existing type 1 or type 2 diabetes, coronary heart disease, heart failure, stroke, cancer diagnosis (other than non-melanoma skin cancer) or treatment in the past 12 months, end-stage organ failure, residence in a long-term care facility, life expectancy \\\u003C24 months\n* Self-report of weight change \\>15 lbs. during prior 3 months\n* Current active weight loss treatment, including research-based commercial weight loss programs (e.g., Weight Watchers, Jenny Craig, HMR, Omada, TOPS), other programs led by trained personnel (professional or lay) at the recruiting clinic or in the local community\n* Taking prescription medications regularly that affect appetite\u002Fweight (e.g., anti-obesity medicines, oral corticosteroids, oral hypoglycemics, etc.) for chronic disease management\n* Planned or prior bariatric surgery (Note: patients who are more than 2 years post bariatric surgery may otherwise be eligible)\n* Screen positive for bulimia nervosa using PHQ- eating disorder module\n* Unable to pass the Revised Physical Activity Readiness Questionnaire (PAR-Q) or obtain physician clearance to participate\n* Active suicidal ideation (PHQ-9 item 9 score ≥1 or SCL-20 item 2 score ≥2) with active plan and\u002For intent\n* Bipolar or psychotic disorder, or pharmacotherapy or psychotherapy (individual or professionally-led group therapy), or brain stimulation therapy for depression or any other psychiatric condition\n* Cognitive impairment based on the Callahan 6-item screener\n* Active alcohol or substance use disorder (including prescription drugs) based on the CAGE Questionnaire Adapted to Include Drugs (CAGE-AID)\n* Current or planned pregnancy or lactating (\\\u003C6 months postpartum)\n* Participation in other behavioral, medical or surgical treatment studies by self-report that conflict with the primary weight loss and depression outcomes of this study\n* Family\u002Fhousehold member of an already enrolled participant or of a study team member\n* Investigator discretion for serious safety or protocol adherence reasons","50 Years","74 Years",{"count":104,"type":20},440,[76],"The goal of this randomized clinical trial is to test the efficacy of a fully digital intervention, combining the Lumen problem-solving therapy virtual coach for depression management with the Diabetes Prevention Program video-based program for weight loss, among racial and ethnic minorities with comorbid depression and obesity. The study aims include:\n\n* Determine the efficacy of the vCare intervention at 6 months. Primary outcomes are weight and depression symptom checklist 20-item (SCL-20) score.\n* Identify predictors of treatment success, defined by achieving clinically significant weight loss (5%) and depression outcomes (50% decline or SCL-20\\\u003C0.5), at 6 and 12 months.\n* Characterize participant experiences and perceptions of the vCare intervention. Eligible participants will be randomized to the early-intervention arm who will receive active treatment for 6 months, followed by maintenance for another 6 months, or the later-intervention arm who will be waitlisted for 6 months and then receive active treatment in the second 6 months.",[108,109],"Obesity","Depression",{"date":87,"type":32},{"date":112,"type":32},"2025-01-21",{"date":114,"type":20},"2028-10-13",{"name":38,"class":39},2,{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":101,"enrollmentInfo":124,"targetDuration":4,"studyType":21,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":40},"100454585","role-of-adiposomes-in-endothelial-dysfunction-100454585","NCT05199454","Role of Adiposomes in Endothelial Dysfunction","Role of Adiposomes in Diabetes-Associated Endothelial Dysfunction and Restorative Effects of Exercise and Metabolic Surgery","Inclusion Criteria:\n\n* BMI ≥ 35 kg\u002Fm2\n* Between ages 18-50 years\n* Not pregnant\n* Diabetic (Current use of diabetes medication or fasting glucose ≥126 mg\u002FdL)\n* Medical clearance to participate in a moderate-intensity exercise program\n\nExclusion Criteria:\n\n* Pregnant women\n* Current smokers\n* Currently abusing alcohol or drugs\n* Chronic heart, liver, or kidney diseases, autoimmune diseases, or cancer\n* Non-English speakers\n* History of allergic reactions to lidocaine",{"count":125,"type":20},60,[76],"The development of type II diabetes (T2D) is strongly associated with obesity and both are well-established risk factors for cardiovascular disease. Knowing that vascular dysfunction is an early event in the development of cardiovascular disease in obese diabetic (OB-T2D) patients, The investigators set their long-term goal to define molecular mechanisms of vascular dysfunction and corrective strategies that target these mechanisms such as physical activity and weight loss. The investigators recently discovered that human adipose tissues release extracellular vesicles (adiposomes) that are efficiently captured by endothelial cells. Adiposomes are known to carry bioactive cargos such as proteins and micro RNAs; however, their lipid content has not been studied nor has their ability to transfer their lipid cargo to endothelial cells. In the current application, the investigators propose to investigate the role of adiposomes in communicating the unhealthy milieu, mainly dysregulated lipids, to endothelial cells in OB-T2D subjects. On top of these lipid species that the investigators propose to be carried by adiposomes are glycosphingolipids (GSLs). These lipids originate from the glycosylation of ceramides, a chemical process that is upregulated in the presence of inflammation and high glucose levels. Preliminary findings showed that in endothelial cells, GSL-rich adiposomes disturb plasma membrane structure and subsequently induce endothelial dysfunction. Moreover, the investigators found that preconditioning endothelial cells with high shear stress (which is an exercise mimetic) protected endothelial cells from the detrimental effects induced by adiposomes. Therefore, the central hypothesis is that adipose tissues in OB-T2D patients release GSL-loaded adiposomes that induce vascular endothelial dysfunction. The researchers propose that exercise and weight loss interventions (bariatric surgery) will restore adipose tissue homeostasis, reduce GSL-loaded adiposomes, and subsequently alleviate vascular risk in OB-T2D patients. The investigators will test the hypotheses by pursuing the following aims: aim 1: Investigate the role of GSL-rich adiposomes in the pathogenesis of endothelial dysfunction in OB-T2D adults; aim 2: Test the effectiveness of exercise training in reducing adiposome-mediated effects on vascular function; and aim 3: Examine changes in adiposome\u002Fcaveolae axis following metabolic surgery and their association with vascular function.",[108,129,130],"Diabetes","Cardiovascular Diseases",{"date":132,"type":32},"2026-08-17",{"date":134,"type":32},"2022-05-16",{"date":136,"type":20},"2026-12-31",{"name":38,"class":39},{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":70,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":21,"phases":146,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":40},"100648796","early-phase-1-haloperidol-for-outpatient-symptom-management-in-patients-diagnosed-with-cannabinoid-hyperemesis-syndrome-in-the-emergrency-department-100648796","NCT07726069","Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department","Inclusion Criteria:\n\n\\- Patients who meet ROME-4 diagnostic criteria for cannabinoid hyperemesis syndrome\n\nExclusion Criteria:\n\n* Already on dopamine agonist\u002Fantagonist therapy for another condition\n* Parkinson's disease\n* Lewy body dementia\n* Men with QTc \\> 450\n* Women with QTc \\> 460\n* Patients with documented allergy to haloperidol\n* Patients with known functional prolactinomas\n* Patients who are breastfeeding\n* Patients under the age of 18\n* Patients who are pregnant\n* Patients who are in the prison system\n* Patients who are unable to consent",{"count":145,"type":20},100,[147],"EARLY_PHASE1","Patients diagnosed with cannabinoid hyperemesis syndrome that are safe for discharge from the emergency department will be sent an outpatient prescription for haloperidol to be used as needed at home. The study goal is to see if having this medication available helps to prevent return emergency department visits for recurrent or persistent symptoms.",[150],"Cannabinoid Hyperemesis Syndrome",[152,153,154,155],"chs","cannabinoid hyperemesis syndrome","haldol","haloperidol","2026-08-13",{"date":132,"type":32},{"date":159,"type":20},"2026-11",{"date":161,"type":20},"2028-01",{"name":38,"class":39},{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":173,"phases":4,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":40},"100531952","the-gut-microbiome-and-serum-metabolites-as-a-biological-mechanism-underlying-pain-in-kidney-transplantation-100531952","NCT06206486","The Gut Microbiome and Serum Metabolites as a Biological Mechanism Underlying Pain in Kidney Transplantation","The Gut Microbiome and Serum Metabolites as a Biological Mechanism Underlying Pain in Kidney Transplantation (Biome-KT)","BIOME-KT","Inclusion Criteria:\n\n* Receiving a kidney transplant at the University of Illinois Hospital \\& Health Sciences System (UI Health) Transplant Center at the University of Illinois Chicago (UIC),\n* Planning to receive a kidney transplant at the UI Health Transplant Center\n* 18 years of age or older (adult), and\n* Understand the study process and provide written informed consent to participate.\n\nExclusion Criteria:\n\n* Having a history of colon cancer or an inflammatory bowel disease\n* Planning to receive a multiorgan transplant (e.g., simultaneous pancreas and kidney transplant).\n* Having a history of Clostridium difficile infection in the preceding 8 weeks.",{"count":172,"type":20},133,"OBSERVATIONAL","Study Summary Nearly half (47%) of people with end-stage kidney disease (ESKD) whose kidney function is restored after kidney transplantation experience chronic pain compared to 19% of adults in the US general population. Pain is associated with comorbid fatigue, depression and anxiety, and withdrawal from usual physical and social activities; resulting in an inability to participate in and enjoy life. Severe pain can result in nonadherence to immunosuppression and treatment protocols and result in an increased risk of rejection, graft loss, and mortality. The role of symbiotic microbes (microbiota) in the gastrointestinal tract, and their functional genes (microbiome), is well established in diseases involving pain. Diet and stress play a major role in synthesis of signaling molecules critical to immunologic, metabolic, and endocrine pathways regulating chronic pain. Dietary patterns change dramatically after transplantation, as recipients move from a restricted \"renal\" diet to a regular diet, often resulting in increased consumption of foods high in sugars and fat. Moreover, psychological stress significantly impairs the function of the microbiome, initiating biological pathways involved in pain, leading to a disproportionate pain burden. Because the microbiome, serum metabolites, and pain are dynamic, our novel investigation will employ a prospective repeated measures design to interrogate the dynamic temporal relationships between the microbiome, metabolites associated with pathways regulating pain, transplantation factors (e.g. immunosuppression, kidney function), changing dietary patterns, and perceived stress, on pain scores before and after kidney transplantation. The investigators posit the gut microbiome, and its byproducts, may partially explain the underlying biological mechanisms of pain Interference in kidney disease. The investigators will address three aims: 1) To determine differential dynamic temporal relationships between microbial composition\u002Ffunctional genes and circulating serum metabolites in KTRs with pain vs no pain, 2) To determine the moderation effects of diet and perceived stress on dynamic temporal relationships between microbiome features, serum metabolites, and pain scores among KTRs, and 3) To use machine learning algorithms to identify host-microbial interactions that are causally linked to pain interference among KTRs. Because kidney function is restored, the kidney transplant model is powerful to study the longitudinal relationships between the microbiome, circulating metabolites and chronic pain in people with ESKD to develop patient-centered interventions to treat pain across the spectrum of CKD.",[176,177],"Kidney Transplant Symptoms","Gut Microbiome",{"date":132,"type":32},{"date":180,"type":32},"2023-10-09",{"date":182,"type":20},"2028-03",{"name":38,"class":39},{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":70,"sex":16,"minAge":4,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":21,"phases":193,"briefSummary":194,"conditions":195,"keywords":197,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":203,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":40},"100461852","patient-navigators-for-childrens-community-mental-health-services-in-high-poverty-urban-communities-100461852","NCT05294042","Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities","Inclusion Criteria:\n\n* African American and Latinx Children between 0 and 14 years of age and their caregiver\n* New referrals on the waitlist for outpatient mental health services; families interested and engaged in social services from two state supported projects.\n* Have been screened and deemed appropriate for services at one of two social service participating community mental health agencies; or engaged in services via navigation projects\n\nExclusion Criteria:\n\n* N\u002FA","14 Years",{"count":192,"type":20},154,[76],"The purpose is to study a model of mental health navigation for African American and Latinx children (0-14 years) in high poverty urban communities focused on reducing key parental attitudinal barriers to care. Reducing persistent racial and ethnic disparities in children's mental health is a national priority and patient navigation is a highly promising approach that is rarely used in children's mental health services. The study will examine the effectiveness of paraprofessional (PP) navigators who have strong community knowledge and waitlist as usual condition (active wailt list \\[AWL\\]. The study will examine specific mechanisms of navigator effectiveness in children's mental health and compare an AWL to provide a rigorous test of the proposed mechanisms. The knowledge gained from this application may be important to reducing disparities and employing the workforce best suited to navigation in the community mental health system. Two community boards, one focused on identifying factors important to supporting navigators at the agencies (Implementation and Sustainability Community Board) will meet quarterly, and the other focused on implications for state and federal policy (Public Policy Board), will meet annually.",[196],"Community Mental Health Services",[198,199,200,201,202],"Child Mental Health Services","Racial and Ethnic Disparities","Urban Poverty","Navigation","Paraprofessional",{"date":132,"type":32},{"date":205,"type":32},"2022-03-03",{"date":207,"type":20},"2027-02-28",{"name":38,"class":39},{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":70,"sex":16,"minAge":216,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":21,"phases":220,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":230,"locationsCount":40},"100644756","multi-site-feasibility-testing-a-meditation-app-for-youth-in-the-legal-system-100644756","NCT07674303","Multi-Site Feasibility Testing a Meditation App for Youth in the Legal System","Improving Psychological Wellbeing and Decreasing Psychological Distress Among Youth in the Legal System: Multi-Site Feasibility Trial of a Mindfulness Meditation App","Inclusion Criteria:\n\n* 13-20 years old\n* In probation or related programming (i.e., in legal programming but not detained) in Oregon or New York State\n* Have access to an Apple\u002FAndroid smartphone\n* Understand and provide assent\u002Fconsent\n* Have legal guardian permission (if under 18 years old)\n* English-speaking, due to norming of instruments\n\nExclusion Criteria:\n\n\\- There are no exclusion criteria.","13 Years","20 Years",{"count":219,"type":20},120,[76],"This multi-site feasibility clinical trial aims to assess the feasibility of implementing a 1-month app-based meditation program with youth in 4 heterogeneous juvenile legal systems across Oregon and New York. The primary question it is designed to answer is: Will youth adequately adhere to the 1-month meditation app across sites? Secondary feasibility outcomes pertain to recruitment, randomization, retention, and survey completion.",[223],"Behavioral Health","2026-08-04",{"date":226,"type":32},"2026-08-07",{"date":228,"type":32},"2026-07-30",{"date":61,"type":20},{"name":38,"class":39},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":70,"sex":16,"minAge":101,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":21,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":116},"100624353","lung-07-advancing-precision-based-lung-cancer-screening-implementation-ai-guided-risk-stratification-and-biomarker-integration-crest-ai-100624353","NCT07408531","LUNG-07: Advancing Precision-Based Lung Cancer Screening: Implementation, AI-Guided Risk Stratification, and Biomarker Integration (CREST AI)","Inclusion Criteria:\n\n* Age 50-80 years at the time of consent\n* Meets at least one of the following LCS eligibility criteria:\n\n  * USPSTF: ≥20 pack-years, currently smoke or quit ≤15 years ago.\n  * Potter: 20 years of smoking, regardless of intensity\n  * ACS: ≥20 pack-years, no restriction on quit time\n* Receiving or scheduled for LDCT through the UI Health Lung Screening Program.\n* Willing to view a short (approximately 2-minute) educational video that explains Sybil AI scoring and LCS, complete the Sybil AI survey (if selected), and\u002For provide blood samples (optional).\n* Able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC IRB ICF and HIPAA authorization.\n* Women of childbearing potential must not be pregnant or breastfeeding. A negative serum or urine pregnancy test is required per institutional practice guidelines.\n* As determined at the discretion of the enrolling physician or protocol designee, the ability of the subject to understand and comply with study procedures for the entire length of the study\n\nExclusion Criteria:\n\n* Inability to undergo LDCT\n* Current diagnosis or history of lung cancer \\\u003C 5 years prior to study enrollment.\n* Life expectancy \\\u003C1 year\n* Active lung infection requiring systemic therapy\n* Vulnerable population, including prisoners and pregnant or nursing women, will not be enrolled due to radiation exposure from LDCT, which is contraindicated in pregnancy.\n* Other major comorbidity, as determined by the study PI\n* Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial.","80 Years",{"count":239,"type":20},2500,[76],"This research study aims to investigate methods for enhancing lung cancer screening. The study will investigate whether an artificial intelligence (AI) tool, known as Sybil, can aid in predicting the risk of lung cancer. The investigators will also examine whether expanding the screening criteria (based on the guidelines of the Potter and American Cancer Society (ACS)) can help identify individuals at risk who are not currently included in the U.S. Preventive Services Task Force (USPSTF) guidelines.",[243],"Lung Cancer Screening","2026-08-03",{"date":246,"type":32},"2026-08-06",{"date":248,"type":32},"2026-03-12",{"date":250,"type":20},"2038-03",{"name":38,"class":39},{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":21,"phases":262,"briefSummary":263,"conditions":264,"keywords":271,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":4},"100650043","bridge-trial-embedding-consumer-grade-mhealth-technologies-into-cardiac-rehabilitation-100650043","NCT07741396","BRIDGE Trial: Embedding Consumer-grade mHealth Technologies Into Cardiac Rehabilitation","BRIDGE Trial: Embedding Consumer-grade mHealth Technologies Into Cardiac Rehabilitation as a Model for Chronic Disease Management","BRIDGE","Inclusion Criteria:\n\n1. Adults aged 18 years or older.\n2. Enrolled in or referred to Phase II Center-based Cardiac Rehabilitation Program.\n3. Have a qualifying cardiovascular diagnosis or event that meets standard eligibility for Phase II Center-based Cardiac Rehabilitation, such as:\n\n   * Acute myocardial infarction\n   * Percutaneous coronary intervention\n   * Coronary artery bypass graft surgery\n   * Chronic heart failure with reduced ejection fraction\n   * Heart valve repair or replacement\n   * Stable angina\n4. Able to ambulate and participate in exercise testing and training as required by the CR program\n5. Ability to speak and read in English\n6. Willing and able to provide informed consent.\n7. Willing to use study-related devices\u002Fapps and complete study assessments.\n\nExclusion Criteria:\n\n1. Not enrolled in or not planning to participate in Phase II Center-based Cardiac Rehabilitation Program.\n2. Presence of a medical, cognitive, psychiatric, or physical condition that, in the opinion of the investigators or CR team, would preclude safe participation in the study or adherence to study procedures.\n3. Severe cognitive impairment or active psychiatric illness that would interfere with informed consent or study participation.\n4. Terminal illness or other serious medical condition that in the judgement of the treating clinician or investigator would likely preclude completion of the study follow-up period. .\n5. Current hospice enrollment or residence in a long-term care facility that would preclude participation in the intervention or completion of study follow-up procedures.\n6. Currently participating in another behavioral or digital health intervention trial that could confound study outcomes.\n7. Inability or unwillingness to use the required mobile devices, applications, or monitoring equipment, if applicable.",{"count":261,"type":20},30,[76],"The purpose of the BRIDGE study is to learn whether supplementing traditional center-based cardiac rehabilitation (CBCR) with a mobile health technology intervention can help patients monitor their health, stay engaged in healthy lifestyle behaviors, better manage cardiovascular risk factors, and improve overall health outcomes.\n\nCardiac rehabilitation is an evidence-based outpatient program designed to help people recover from heart-related conditions through supervised exercise, education, counseling, and support for healthy lifestyle changes. Although cardiac rehabilitation is highly recommended and beneficial, many patients do not receive the full benefits of the program. Some patients attend fewer sessions than recommended, and many find it difficult to maintain healthy habits outside of the clinic, such as regular physical activity, heart-healthy eating, taking medications as prescribed, monitoring blood pressure, and managing weight.\n\nThis study will test whether combining CBCR with mobile health tools may improve participation and support healthy behaviors at home. Mobile health tools include mobile phone applications, connected devices such as a weight scale, blood pressure monitor, and activity tracker, as well as personalized text messages designed to encourage and support healthy self-care.\n\nThis study will help determine whether these mobile health tools can make cardiac rehabilitation more effective and help patients maintain healthy behaviors beyond the clinic setting.",[265,266,267,268,269,270],"Acute Myocardial Infarction (AMI)","Percutaneous Coronary Intervention (PCI)","Coronary Artery Bypass Graft Surgery (CABG)","Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)","Heart Valve Repair or Replacement","Stable Angina Pectoris",[272,273,274,275],"cardiac rehabilitation","mHealth","digital tool","consumer-grade technology","2026-07-29",{"date":244,"type":32},{"date":279,"type":20},"2026-09-01",{"date":281,"type":20},"2027-07-30",{"name":38,"class":39},{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":21,"phases":294,"briefSummary":295,"conditions":296,"keywords":298,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":40},"100622411","we-need-to-feed-facilitating-enteral-education-for-discharge-100622411","NCT07383272","We Need to FEED: Facilitating Enteral Education for Discharge","We Need to F.E.E.D.: Facilitating Enteral Education for Discharge - Improving the Quality of Discharge for Pediatric Patients With Enteral Tubes","WeNeed2FEED","Inclusion Criteria:\n\n* Patients must be within the age range of 0 to 17 years.\n* Patients who have recently had an enteral feeding tube placed (G-tube, J-tube, GJ-tube, or NG-tube).\n* The patient must be hospitalized at the time of the study and scheduled for discharge within the study period (before discharge).\n* A legal guardian must be available to participate in the study, complete questionnaires, and engage in the educational sessions.\n* Both the pediatric patient and their caregiver must be willing to participate in the study, including completing surveys and receiving educational materials.\n\nExclusion Criteria:\n\n* Patients who have had an enteral tube (G-tube, J-tube, GJ-tube, or NG-tube) for more than a short period (e.g., those who have had tubes in place for more than 3 months) may be excluded, as the study is focused on newly placed feeding tubes.\n* Patients aged 18 years or older are excluded from the study, as the project targets pediatric patients specifically.\n* If the caregiver (or the child, where applicable) has significant cognitive or language barriers that would prevent them from understanding the educational content or completing the surveys, they may be excluded.\n* Families who do not speak English may be excluded.\n* Patients with significant comorbidities or unstable clinical conditions that would make participation in the discharge education protocol impractical will be excluded. This includes, but is not limited to, patients with severe respiratory failure requiring nitric oxide therapy, hemodynamic instability requiring blood pressure medications (e.g., vasopressors), or other acute medical conditions requiring active intensive care. Patients who are stable and preparing for discharge, even after a prolonged NICU or PICU stay, will not be excluded.\n* Only legal guardian can enroll child.\n* Patients whose caregivers are unable or unwilling to adhere to study protocols (e.g., participating in follow-up assessments or completing questionnaires) may be excluded to ensure consistency and reliable data collection.","17 Years",{"count":293,"type":20},20,[76],"Aim: We need to FEED (Facilitating Enteral Education for Discharge) project aims to streamline and enhance the discharge process for pediatric patients with enteral nutrition (including G-tubes, J-tubes, GJ-tubes, and NG-tubes) and ultimately create enteral discharge protocol. The aim of the study is to describe the effectiveness of the discharge education program for children with enteral tubes on caregiver knowledge and determine the impact of the program on unplanned ER, Urgent care or clinic visits. By ensuring that all necessary supplies, orders, and follow-up appointments are in place prior to discharge, and by providing comprehensive education and support to parents, the project seeks to improve patient outcomes, reduce healthcare utilization, enhance coordination and communication among healthcare providers.",[297],"Enteral Nutrition Feeding",[299,300,301,302,303,304,305,306],"education","feeding tube","g tube","ng tube","gj tube","parent education","pediatrics","patient education",{"date":308,"type":32},"2026-07-31",{"date":310,"type":20},"2026-08-30",{"date":312,"type":20},"2028-05-01",{"name":38,"class":39},{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":21,"phases":324,"briefSummary":325,"conditions":326,"keywords":328,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":336,"leadSponsor":338,"locationsCount":40},"100649060","physical-activity-intervention-for-individuals-newly-diagnosed-with-ms-100649060","NCT07731659","Physical Activity Intervention for Individuals Newly Diagnosed With MS","Physical Activity Behavior Change Intervention in Persons Newly Diagnosed With Multiple Sclerosis - ActivNMS Trial - COM-B Construct Testing","ActivNMS","Inclusion Criteria:\n\n* aged 18 years or older\n* self-reported diagnosis of MS by a neurologist within the past 2 years\n* relapse-free for the past 30 days\n* ability to speak and read English as the primary language\n* internet and e-mail access\n* willingness to complete study protocol\n* ambulatory without an assistive device (PDDS \\\u003C 3)\n* insufficiently active (Godin Leisure-Time Exercise Questionnaire (GLTEQ) \\\u003C 14)\n* visual ability and literacy to read newsletter with font size 14 points\n* on a stable disease-modifying therapy for 6 months\n\nExclusion Criteria:\n\n* pregnant\n* have an elevated risk for undertaking strenuous or maximal exercise based on two or more affirmatives on the Physical Activity Readiness Questionnaire (PAR-Q)",{"count":323,"type":20},50,[76],"The proposed study is a parallel-group randomized controlled trial (RCT) designed to establish the behavioral mechanism underlying a 16-week physical activity (PA) behavioral intervention through its effects on the Capability-Opportunity-Motivation-Behavior (COM-B) constructs. The success of this study will provide robust evidence for supporting its refinement via refined COM-B constructs and Behavior Change Techniques to facilitate or maximize the intervention effects on PA levels, which will be examined in the subsequent clinical trial. Such an approach will involve an RCT that examines the effects of a 16-week remotely delivered, Internet-based PA behavioral intervention via video behavioral coaching and newsletter compared with a waitlist control (WLC) condition for yielding improvements in the COM-B constructs among persons newly diagnosed with multiple sclerosis (PNDwMS, disease duration ≤ 2 years). The investigators hypothesize that participants in the PA behavioral intervention condition will demonstrate greater improvements in the COM-B constructs than those in the WLC condition. The investigators plan to recruit 50 PNDwMS, with a distribution of 25 participants in the PA behavioral intervention and 25 participants in the WLC condition. The primary outcomes are the self-report COM-B constructs (listed in the Outcomes section), which will be remotely assessed at baseline and post-intervention through an online battery of questionnaires via REDCap.\n\nSpecific Aim 1: to establish mechanisms for the behavior change intervention using a 2-arm pilot randomized controlled trial (RCT) of the intervention compared with the waitlist control (WLC) among PNDwMS. The investigators hypothesize that the 16-week COM-B-based behavioral intervention delivered by one-on-one behavior coaching and newsletters will result in larger changes in COM-B constructs (i.e., knowledge, outcome expectations, goal, intention, behavioral regulation, self-efficacy, fatigue, social support, and social and environmental barriers) than in the WLC group.\n\nSpecific Aim 2: to examine change in self-reported physical activity levels in PNDwMS who received the COM-B-based intervention compared with those who are in the waitlist control condition. The investigators hypothesize that the 16-week COM-B-based behavioral intervention will result in larger changes in self-reported physical activity outcomes than in the WLC group.",[327],"Multiple Sclerosis",[329,330,331],"Physical Activity","Newly Diagnosed MS","Behavioral Intervention","2026-07-25",{"date":334,"type":32},"2026-07-28",{"date":89,"type":20},{"date":337,"type":20},"2028-10-01",{"name":38,"class":39},{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":16,"minAge":217,"maxAge":346,"enrollmentInfo":347,"targetDuration":4,"studyType":21,"phases":348,"briefSummary":349,"conditions":350,"keywords":359,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":370,"leadSponsor":372,"locationsCount":116},"100648842","tissue-preservation-in-immediate-1c-implants-using-an-anatomical-prefabricated-healing-abutment-100648842","NCT07727980","Tissue Preservation in Immediate 1C Implants Using an Anatomical Prefabricated Healing Abutment","Aharct","Inclusion Criteria:\n\n* Willing to sign an IRB-approved informed consent and HIPAA authorization form prior to participation.\n* Between the ages of 20 and 75 years old.\n* ASA Classification I and II.\n* Hopeless maxillary or mandibular posterior teeth, eligible for immediate implantation, and with intact\u002Fsuccessfully restored adjacent teeth.\n* Willing to perform tasks associated with the study and to attend all study visits.\n\nExclusion Criteria:\n\n* HbA1c \\>6.5%) as per a chairside test (Siemens Bayer DCA 2000+);\n* smoker (any status);\n* immunodeficiency;\n* history of head and neck radiotherapy;\n* intake of bone anti-resorptive drugs;\n* cysts or tumors in the area;\n* self-reported pregnancy;\n* poor oral hygiene;\n* active periodontal disease;\n* acute endodontic infection and pus discharge on the site itself and adjacent areas;\n* lack of mutually protected occlusion;\n* insufficient inter-occlusal clearance (\\\u003C15 mm);\n* sites with an existing midfacial mucogingival recession\u002Fdeficiency (scar tissue);\n* sites with a high-scalloped, thin biotype.\n\nThose who appear to qualify will have a CBCT scan taken with an open bite and proper retractions of the cheek, lips, and tongue (standard of care), and the following inclusion criteria, based on the CBCT results, must be present in order for the subject to be fully enrolled in the study:\n\n* Sites with an intact or minimally damaged facial bone plate measuring greater than 1 mm in thickness;\n* Sites with at least 5 mm of healthy bone between the socket apex and the relevant anatomical structure (e.g., the maxillary sinus floor in the maxilla or the inferior alveolar nerve, submandibular\u002Fsublingual fossa, mental foramen, or anterior loop of the inferior alveolar nerve in the mandible);\n* In multirooted molar sockets, the presence of a short root trunk and an interradicular septum with a minimum height of 5 mm and a thickness of 3 mm.","75 Years",{"count":261,"type":20},[76],"The goal of this clinical trial is to evaluate whether an anatomical prefabricated healing abutment (AHA) improves tissue preservation and clinical outcomes following immediate implant placement after tooth extraction in adults. Although immediate implant placement is a well-established treatment for replacing missing teeth, healing can result in changes to the surrounding bone and soft tissues that may affect the esthetic appearance, function, and long-term stability of the implant-supported restoration. This study will compare an anatomical healing abutment, designed to mimic the natural tooth emergence profile and support peri-implant tissues during healing, with a conventional healing abutment. The primary objectives are to determine whether the AHA better preserves soft tissue contours and alveolar bone, improves implant positioning accuracy and tissue stability during healing, and differs from a conventional healing abutment in complications or adverse events. Eligible participants will be adults requiring extraction of a hopeless tooth in the posterior maxilla or mandible who are suitable candidates for immediate implant placement. Following tooth extraction and implant placement, participants will receive either an anatomical prefabricated healing abutment or a conventional healing abutment and will return for scheduled follow-up visits over approximately 12 months to assess healing, implant stability, and changes in the surrounding hard and soft tissues. Researchers will collect clinical measurements, digital intraoral scans, photographs, and radiographic images throughout the study. Additional research imaging will be used to generate three-dimensional models to measure tissue volume changes and implant position accuracy. Specialized software will compare changes between the two groups over time. Safety will be evaluated by monitoring participants for complications, discomfort, inflammation, implant-related problems, and other adverse events throughout follow-up. All procedures will be performed by trained dental professionals using established clinical protocols. The results may improve understanding of how healing abutment design influences tissue preservation after immediate implant placement and help optimize future implant therapy by supporting better functional, esthetic, and long-term outcomes.",[351,352,353,354,355,356,357,358],"Tooth Loss","Dental Implant","Clinical Trials","Randomized Controlled Trial","Immediate Dental Implant Placement","Molar Extraction Socket","Maxilla","MANDIBLE",[360,361,362,363,364,365],"3-dimensional imaging","wound healing","healing abutments","immediate implant placement","soft tissue dimensional alterations","implant position accuracy","2026-07-24",{"date":368,"type":32},"2026-07-27",{"date":34,"type":20},{"date":371,"type":20},"2028-09",{"name":38,"class":39},{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":21,"phases":381,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":40},"100649320","phase-2-rimo-hnc-neo1-phase-2-study-of-rimo-301-and-hypofractionated-radiotherapy-with-pembrolizumab-for-the-neoadjuvant-treatment-of-resectable-locally-advanced-head-neck-cancer-100649320","NCT07732634","RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer","RiMO-HNC-NEO1","Inclusion Criteria:\n\n* Diagnosis of head and neck cancer that requires surgical resection\n* Must have at least one lesion that is clinically accessible to RiMO-301 injection and amenable to receiving hypofractionated radiotherapy\n* The selected target lesions must be measurable on cross-sectional imaging, and repeated measurements at the same location should be achievable\n* Target tumor not in the previously irradiated field or in the field irradiated at least six months prior to RiMO-301 injection, and with no complications from the prior radiation course\n* Patients must have recovered from acute toxic effects (≤ grade 1 CTCAEv6) of previous cancer treatments prior to enrollment\n* Patients with locally advanced, resectable head and neck cancer:\n\n  * suitable to receive a PD-1 inhibitor (pembrolizumab) as a standard of care in the discretion of the treating physician or Principal Investigator\n  * suitable to receive hypofractionated radiotherapy as a standard of care in the discretion of the treating physician or Principal Investigator\n* Have adequate bone marrow reserve:\n\n  * Absolute neutrophil count ≥1.5x109 cell\u002FL\n  * Platelet count ≥100x109 cell\u002FL\n  * Hemoglobin at least ≥9.0 g\u002FdL unless confirmed by treating physician as not posing any increased harm to patient and approved by Sponsor (transfusion is allowed to achieve hemoglobin of ≥9.0 g\u002FdL 14-days prior to dosing)\n* Have adequate liver function:\n\n  * Total serum bilirubin no more than 1.5x upper limit of normal (ULN)\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5x ULN or ≤5.0x ULN in case of documented hepatic metastasis\n  * Alkaline phosphatase ≤5x ULN\n* Have a life expectancy of at least 12 weeks (in the opinion of the investigator)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Females with childbearing potential should be using adequate contraceptive measures from the time of screening until 6 months after study discontinuation, should not be breastfeeding, and must have a negative pregnancy test prior to start of dosing\n* Patients must sign a study-specific informed consent form prior to study entry.\n\nExclusion Criteria:\n\nDiagnosis other than resectable, locally advanced head and neck cancers\n\n* HPV associated head and neck cancer\n* Nasopharynx head and neck cancer\n* Have signs or symptoms of end-stage failure, major chronic illnesses other than cancer, or any severe concomitant conditions\n* Symptomatic central nervous system metastases and\u002For carcinomatous meningitis\n* Has received any approved or investigational anti-neoplastic agent or immunotherapy other than PD-1 inhibitors, pembrolizumab, within 4 weeks prior to RiMO-301 injection.\n* Patients who are intolerant to pembrolizumab\n* Active autoimmune disease that has required systemic treatment in the past 2 years\n* Ongoing clinically significant infection at or near the incident lesion\n* Major surgery over the target area (excluding placement of vascular access) ≤21 days from the beginning of the study drug or minor surgical procedures ≤7 days. No waiting is required following implantable port, enteral feeding tube, and catheter placement\n* Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that would make the patient inappropriate for enrollment in this study\n* Has any mental or medical condition that prevents the patient from giving informed consent or participating in the trial\n* Pregnant and nursing women are excluded because of the potential teratogenic effects and potential unknown effects on nursing newborns\n* Patients with a target lesion in the field that had complications from prior radiotherapy that are not amenable to repeat irradiation in the discretion of the treating physician or Principal Investigator\n* Patients with lesions that have significant blood vessel involvement (such as carotid artery encasement) or other major structures",{"count":293,"type":20},[23],"The primary objective is to evaluate major pathologic response after RiMO-301 with hypofractionated radiotherapy and a PD-1 inhibitor (pembrolizumab), as assessed by clinical response rate using iRECIST criteria; determine event-free survival for up to 12 months; and determine overall survival for up to 24 months. The secondary objectives include determining event-free survival for up to 12 months and overall survival for up to 24 months.",[384,385,386],"Head and Neck Cancer","Head Cancer","Neck Cancer","2026-07-23",{"date":276,"type":32},{"date":390,"type":20},"2026-08",{"date":392,"type":20},"2031-08",{"name":38,"class":39},{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":12,"sex":400,"minAge":17,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":21,"phases":403,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":411,"leadSponsor":413,"locationsCount":40},"100645900","phase-3-effects-metabolic-mechanisms-and-predictors-of-response-to-acupuncture-in-treating-psychoneurological-symptoms-among-breast-cancer-survivors-100645900","NCT07695948","Effects, Metabolic Mechanisms and Predictors of Response to Acupuncture in Treating Psychoneurological Symptoms Among Breast Cancer Survivors","Inclusion Criteria:\n\n* ≥ 18 years of age\n* With histologically confirmed Stage 0-III ER\u002FPR-positive HER2-negative breast cancer\n* Currently receiving adjuvant endocrine therapy\n* Completed their primary cancer treatment (e.g., surgery, radiotherapy, chemotherapy) at least 3 months prior to recruitment\n* Acupuncture-naïve\n* Have self- reported pain, fatigue, and sleep disturbance in the last month with an average severity rating ≥ 3 (0-10 numeric rating scale) for at least 2 of the 3 symptoms.\n\nExclusion Criteria:\n\n* Taking methylsulfonylmethane or glutathione supplements\n* Physically or cognitively unable to complete the study procedures\n* Pregnant","FEMALE",{"count":402,"type":20},252,[404],"PHASE3","The purpose of this study is to examine the effect, mediators and predictors of treatment response of acupuncture in treating the psychoneurological symptom cluster (pain, fatigue, sleep disturbance) among breast cancer survivors.",[54],"2026-07-10",{"date":409,"type":32},"2026-07-13",{"date":279,"type":20},{"date":412,"type":20},"2031-08-31",{"name":38,"class":39},{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":21,"phases":424,"briefSummary":425,"conditions":426,"keywords":427,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":432,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":40},"100547614","exercise-rehabilitation-program-in-ms-who-use-wheelchairs-as-a-primary-mobility-device-100547614","NCT06410261","Exercise Rehabilitation Program in MS Who Use Wheelchairs as a Primary Mobility Device","Randomized Pilot Study Evaluating the Effect of a 6-Month Exercise Rehabilitation Program on Physical and Cognitive Function in Persons With MS Who Use Wheelchairs as a Primary Mobility Device","MSGH","Inclusion Criteria:\n\n* diagnosis of MS\n* age above 18 years\n* no relapse within last 30 days\n* use of wheelchair for mobility in the community\n* ability to walk at least 50 feet (or 65 steps) using an assistive device\n* low risk for contraindications of physical activity indicated by no more than a single \"yes\"\n* response on the Physical Activity Readiness Questionnaire (PAR-Q)\n* willingness to complete the assessments and undergo randomization\n\nExclusion Criteria:\n\n* no diagnosis of MS\n* less than 18 years of age\n* not relapse-free within the last 30 days\n* no use of wheelchair as primary mobility device\n* no ability to walk for at least 50 feet (or 65 steps)\n* high risk for contraindications based on more than a single \"yes\" response on the PAR-Q\n* not willing to complete the testing procedures and undergo randomization",{"count":423,"type":20},24,[76],"Approximately 50% of people with multiple sclerosis (MS) use a wheelchair within 30 years of the initial diagnosis. Wheelchair use in MS is often associated with fatigue as a consequence of muscle weakness. Indeed, fatigue, a prevalent consequence of MS, often becomes debilitating and exhausts energetic resources when carrying-out tasks of daily life and\u002For interacting with the community, as these require ambulatory mobility. This experience of excessive fatigue has its roots in muscle weakness and results in reliance on a wheelchair for mobility, and the dependency on a wheelchair may further reduce muscular strength, particularly of the lower extremities. We propose that wheelchair users with MS can increase muscular strength through a personalized exercise rehabilitation, and this in turn will improve ambulatory performance and possibly reduce fatigue. To date, no research has examined the effects of this specific exercise rehabilitation program (GH method) on physical function and other disease-related outcomes in persons with MS who use wheelchairs as a primary mobility device.",[327],[428,429,430,431],"Exercise","Rehabilitation","Physical function","Cognition",{"date":409,"type":32},{"date":434,"type":32},"2024-04-29",{"date":436,"type":20},"2027-07-31",{"name":38,"class":39},{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":21,"phases":448,"briefSummary":450,"conditions":451,"keywords":454,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":467,"leadSponsor":469,"locationsCount":40},"100647131","phase-4-antibiotics-after-incision-and-drainage-to-prevent-fistula-formation-after-first-episode-of-perianal-abscess-100647131","NCT07704359","Antibiotics After Incision and Drainage to Prevent Fistula Formation After First Episode of Perianal Abscess","Randomized Antibiotics for Prevention of Fistula After Incision and Drainage of First-Episode Perianal Abscess (RAPID): A Randomized Controlled Trial","RAPID","Inclusion Criteria:\n\n* Age 18 years or older\n* First episode of perianal abscess requiring incision and drainage\n* Able to provide informed consent\n* English or Spanish speaking patient\n* Treating surgical team has determined that incision and drainage is clinically indicated as part of standard care\n\nExclusion Criteria:\n\n* Known fistula-in-ano at presentation\n* Prior perianal abscess within 12 months\n* History of inflammatory bowel disease, including Crohn's disease or ulcerative colitis\n* Known or suspected anorectal malignancy\n* Necrotizing soft tissue infection or Fournier's gangrene\n* Systemic infection or sepsis\n* Significant surrounding cellulitis or extensive soft-tissue infection for which antibiotics are clinically indicated\n* Immunocompromised or immunosuppressed status, including active chemotherapy or radiation therapy, history of transplant, chronic systemic steroids, biologic immunosuppressive therapy, advanced or uncontrolled HIV\u002FAIDS, or other clinically significant immunosuppression\n* Cardiac condition requiring antibiotic prophylaxis or antibiotic therapy for procedures involving infected tissue\n* Need for non-study antibiotics at the time of enrollment for another infection or medical indication\n* Contraindication, allergy, or intolerance to all study antibiotic regimens\n* Pregnant\n* Prisoner\n* Minor\n* Adult unable to provide informed consent",{"count":447,"type":20},236,[449],"PHASE4","The goal of this clinical trial is to learn if antibiotics can prevent the formation of fistula-in-ano after incision and drainage of a first time of perianal abscess in adults. A perianal abscess is a collection of infected fluid near the anus. A Fistula-in-ano is an abnormal tunnel that can form between the anal canal and the skin after an abscess.\n\nThe main questions it aims to answer are:\n\nDoes taking antibiotics after incision and drainage of a perianal abscess lower the chance of developing a Fistula-in-ano? What medical problems or side effects do participants have after taking antibiotics or not taking antibiotics?\n\nResearchers will compare participants who recieve antibiotics after abscess drainage with paticipants who do not recieve antibiotics after abscess drainage, to see if antibiotics lower the chance of developing a Fistula-in-ano.\n\nParticipants will:\n\nBe randomly assigned to recieve antibiotics for 7 days after abscess incision and drainage or to not recieve antibiotics after abscess incision and drainage.\n\nAttend follow-up clinic visits after incision and drainage as part of their standard of care.\n\nComplete follow-up phone call about 12 months after incision and drainage. Allow the study team to review their medical record for abscess treatment, symptoms, recurrence, fistula-in-ano formation, additional procedures, and antibiotics side effects.",[452,453],"Perianal Abscess","Anal Fistula",[455,456,457,458,459,460,461,462],"Perianal abscess","Anal fistula","Fistula-in-ano","Incision and Drainage","Antibiotics","Amixicillin clavulanate","Metronidazole","Ciprofloxacin","2026-07-09",{"date":465,"type":32},"2026-07-15",{"date":244,"type":20},{"date":468,"type":20},"2029-08-03",{"name":38,"class":39},{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":70,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":173,"phases":4,"briefSummary":478,"conditions":479,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":481,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":40},"100631259","apple-watch-evaluation-of-endodontics-occupational-stress-100631259","NCT07498348","Apple Watch Evaluation of Endodontics Occupational Stress","Inclusion Criteria for Primary Subjects (endodontics residents) :\n\n* Active enrollment in an accredited endodontics residency program during the data-collection period\n* Routine clinical involvement in primary root canal treatment and\u002For retreatment\n* Willingness to wear a wrist-worn heart rate monitoring device during clinical sessions\n* Willingness to complete the Perceived Stress Questionnaire (PSQ) at baseline and at the conclusion of participation\n* Absence of medical or dermatologic conditions that would preclude safe or accurate wrist-worn heart rate monitoring\n\nInclusion Criteria for secondary Subjects (Patients):\n\n* Scheduled to receive standard endodontic care with a participating endodontics resident during the study period\n* Willingness to allow the presence of a non-intervening observer\n* Willingness to allow collection of minimal, approved visit-level variables\n* Adult patients able to provide written informed consent\n* Minor patients (under 18 years of age) with parent or legally authorized representative permission\n* Assent obtained from minors as follows:\n* Verbal assent for minors aged 7-12 years\n* Written assent for minors aged 13-17 years\n* No formal assent required for children under 7 years of age (developmentally appropriate explanation provided when feasible)\n* Ability of patient or legally authorized representative to understand and communicate in English\n\nExclusion Criteria for Primary Subjects (endodontics residents) :\n\n* Not engaged in clinical endodontic care during the study window\n* Known dermatologic, cardiovascular, neurologic, or other medical conditions that could interfere with safe or accurate heart rate monitoring\n* Unwilling or unable to provide informed consent or comply with study procedures\n\nExclusion Criteria for secondary Subjects (Patients):\n\n* Decline consent, permission, or assent\n* Withdraw participation at any time\n* Prisoners or individuals under custodial supervision\n* Pregnant patients",{"count":477,"type":20},12,"* This study will enroll approximately 12 endodontists (primary subjects) and approximately 120 patients (secondary subjects) undergoing routine endodontic treatment (primary root canal treatment or retreatment), resulting in approximately 120 observed treatment sessions. Patients will be treated as part of standard clinical care and will not receive any experimental intervention.\n* Participating endodontists will wear an Apple Watch to continuously monitor heart rate (HR) during routine endodontic procedures. The Apple Watch contains built-in physiological sensors that automatically record heart rate. HR data are stored locally in the Apple Health app on a study-designated iPhone assigned for research use and handled solely by the Principal Investigator (PI). No real-time data transmission or cloud-based sharing occurs during data recording. At designated intervals, the PI will use the Apple Health app's built-in \"Export Health Data\" function, which generates a ZIP file containing an export.xml file with sensor-recorded data. The ZIP file will be uploaded directly from the study iPhone to a secure, university-approved UI Box Health Data Folder designated for the study. No research-specific Apple ID, cloud account, or third-party data-sharing platform will be used.\n* A trained, non-intervening observer will record start and stop timepoints of predefined endodontic treatment stages to align HR signals with procedural phases. These stages include patient presentation, examination, informed consent, local anesthesia administration, rubber dam placement, access cavity preparation, root canal instrumentation, obturation, and final radiographic assessment. The observer will document only minimal, non-identifiable procedural variables necessary for analysis, including treatment type (primary root canal treatment or retreatment), treatment difficulty level (based on the AAE Endodontic Case Difficulty Assessment), and patient age category. No patient identifiers or protected health information (PHI) will be recorded.\n* Each participating endodontist will complete the Perceived Stress Questionnaire (PSQ) two times in total at baseline and at the conclusion of study participation to assess perceived stress levels and evaluate associations between baseline stress and physiological stress responses during treatment. The PSQ requires approximately 5 minutes to complete. Endodontists will not complete questionnaires for individual patient encounters. HR data and permitted procedural variables will be coded, securely stored in the UI Box Health Data Folder, and analyzed to assess HR variation across endodontic treatment stages and treatment difficulty levels. No additional patient identifiers or PHI will be collected beyond what is specified above.",[480],"Occupational Stress",{"date":407,"type":32},{"date":483,"type":20},"2026-08-01",{"date":485,"type":20},"2027-06-15",{"name":38,"class":39},{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":70,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":173,"phases":4,"briefSummary":496,"conditions":497,"keywords":498,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":500,"startDateStruct":501,"completionDateStruct":502,"leadSponsor":504,"locationsCount":40},"100620324","monitoring-occupational-dental-stress-using-apple-watch-100620324","NCT07356141","Monitoring Occupational Dental Stress Using Apple Watch","Apple Watch Assessment of Dental Stress in Special Needs Treatment","Inclusion Criteria:\n\n* Students (primary subjects) inclusion criteria: After IRB approval, non-supervisory staff or research team members will invite potential participants via UIC email\u002Flistservs. Interested students will be screened confirming: (a) good academic standing and current clinical assignment, (b) routine provision of care to both special-needs and non-special needs patients during the data-collection window, (c) willingness to wear an Apple Watch during sessions and complete baseline\u002Fend PSQ, and (d) absence of medical\u002Fdermatologic conditions that would preclude safe\u002Faccurate wrist-worn monitoring. Screening and consent occur privately and outside evaluative contexts.\n* Patient (secondary subjects) Inclusion criteria: Patients will be screened at the point of care when already scheduled with a participating student. A pre-visit check confirms capacity to consent (or availability of a legally authorized representative\u002Fparent\u002Fguardian). For minors and\u002For special needs patients, LAR permission will be obtained in addition to assent to the research. The following criteria will be considered:\n* Minors and\u002For Special-needs patients who are scheduled for standard clinical care with a participating student during the study period may be enrolled as secondary subjects provided that their parent\u002Fguardian or legally authorized representative (LAR) grants permission during the consent process and the patient assents to the research when appropriate.\n* Adult Patients with capacity who are scheduled for standard clinical care with a participating student during the study period may be enrolled as secondary subjects provided that are willing to provide informed consent.\n* Willing to allow an observer and collection of minimal visit-level variables (behavior\u002Fcooperation score, sedation status, broad procedure category).\n* Patients and\u002For their parent(s), guardian(s), or legally authorized representative(s) providing consent must be able to understand and communicate in English.\n\nExclusion Criteria:\n\n* Students (primary subjects) Exclusion criteria:\n* Not assigned to patient-care rotations during the study window.\n* Known dermatologic, cardiovascular, neurologic, or other medical conditions that would interfere with safe or accurate HR monitoring or tolerability of a wrist device.\n* Unwilling or unable to provide consent or follow procedures.\n* Patients (secondary subjects) Exclusion criteria:\n* Declines consent\u002Fpermission\u002Fassent or withdraws at any time.\n* Prisoners or individuals under custodial supervision.\n* Pregnant women",{"count":495,"type":20},10,"* This study will enroll 10 dental students (primary subjects) and up to 200 patients (secondary subjects), approximately 10 special-needs and 10 non-special-needs encounters per student, totaling about 200 treatment sessions.\n* Students will wear an Apple Watch to continuously monitor heart rate (HR) during routine care. The Apple Watch contains built-in physiological sensors that automatically record heart rate and heart rate variability. These data are stored locally in the Apple Health app on a study-designated iPhone that is assigned for the research and handled solely by the Principal Investigator (PI). No real-time transmission or cloud-based sharing occurs during data recording. No additional apps, accounts, or third-party software are used. At designated intervals, the PI will use the health app's built-in \"Export Health Data\" function on the study iPhone. This function generates a ZIP file containing an export.xml file with sensor-recorded data. The PI will then upload the ZIP file from the study iPhone directly to a secure, university-approved UI Box Health Data Folder designated for the study. No research account will be set up for this purpose.\n* A trained observer will record start\u002Fstop timepoints of procedure phases (e.g., seating, anesthesia start, operative phase, dismissal) to align with HR signals and will document only minimal patient variables needed for analysis: behavior\u002Fcooperation score (e.g., Frankl), sedation status, and broad procedure category (e.g., preventive, restorative, surgical).\n* Each dental student will complete the Perceived Stress Questionnaire (PSQ) only once at the beginning of the study to stablish a baseline measure of stress. The Questionnaire takes approximately 5 minutes to complete. Students do not need to complete the PSQ for each patient encounter. Student HR data and permitted minimal patient variables will be coded and de-identified, stored securely in UI Box Health Data Folder, and analyzed to compare special-needs vs non-special-needs encounters and to evaluate associations between student HR and the listed patient factors. No additional patient identifiers or PHI will be collected beyond what is specified above.",[480],[499],"stress",{"date":407,"type":32},{"date":483,"type":20},{"date":503,"type":20},"2027-10",{"name":38,"class":39},{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":509,"acronym":510,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":21,"phases":514,"briefSummary":515,"conditions":516,"keywords":520,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":528,"locationsCount":529},"100618524","phase-2-fimdash-food-is-medicine-intervention-to-promote-healthy-eating-and-blood-pressure-control-100618524","NCT07332741","FIM+DASH: Food is Medicine Intervention to Promote Healthy Eating and Blood Pressure Control","FIM+DASH","Inclusion Criteria:\n\n* Adults aged ≥18 years; diagnosis of hypertension in Electronic health record or most recent clinic blood pressure meeting inclusion thresholds (systolic blood pressure ≥130 mmHg and\u002For diastolic blood pressure ≥80 mmHg); BMI ≥30 kg\u002Fm²; able and willing to complete survey instruments and assessment procedures; able to speak\u002Fread English; access to a smartphone with text-messaging capability.\n\nExclusion Criteria:\n\n* inability to speak\u002Fread English; cognitive impairment that precludes informed consent or participation; severe food allergies or medically necessary dietary restrictions that would preclude adoption of a DASH eating pattern; inability to cook at home; current treatment for cancer; self-reported history of a recent major cardiovascular event within the past 12 months (myocardial infarction, cerebrovascular accident, cardiac surgery, or hypertensive emergency); known advanced liver or renal disease; severe mental illness that would preclude participation; pregnancy. Individuals with lactose intolerance will not be excluded because low-lactose alternatives are available within the intervention.",{"count":513,"type":20},150,[23],"The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?",[517,518,519],"Hypertension","Hypertension (HTN)","Obesity & Overweight",[521,517,108,522],"Food is Medicine","Nutrition","2026-07-08",{"date":407,"type":32},{"date":526,"type":32},"2026-05-22",{"date":36,"type":20},{"name":38,"class":39},4,{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":70,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":21,"phases":537,"briefSummary":538,"conditions":539,"keywords":541,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":40},"100633929","effects-of-delay-in-hearing-assistive-technology-100633929","NCT07533071","Effects of Delay in Hearing Assistive Technology","Inclusion Criteria:\n\n* Comfortable conversing in English\n\nExclusion Criteria:\n\n* Speech or hearing disorder",{"count":125,"type":20},[76],"Wireless assistive listening systems can dramatically improve intelligibility in noisy environments, but they are cumbersome to use. Digital consumer devices, such as smartphones, could be more accessible and user-friendly, but they suffer from transmission delays that could be disturbing to listeners. Delay has been studied extensively for in-ear devices such as hearing aids, but not for remote microphone systems. This study aims to characterize the tolerable delay for wireless remote microphones both for both the user's own speech and for external sounds. This will provide valuable information for engineers designing next-generation assistive listening systems.",[540],"Audio Processing Delay",[542,543,544,545,546],"Audio","Hearing","Latency","Assistive Listening","Wireless Microphone","2026-07-07",{"date":463,"type":32},{"date":550,"type":32},"2026-04-15",{"date":552,"type":20},"2028-08",{"name":38,"class":39},{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":560,"minAge":17,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":21,"phases":563,"briefSummary":564,"conditions":565,"keywords":567,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":573,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":40},"100600933","prison-based-hiv-partner-notification-100600933","NCT07103928","Prison-Based HIV Partner Notification","Inclusion Criteria:\n\n* HIV-diagnosed\n* Sexually active (penile-vaginal or penile-anal) and\u002For sharing injection equipment during the year before incarceration\n\nExclusion Criteria:\n\n* Incarcerated more than 5 years","MALE",{"count":562,"type":20},216,[76],"Assisted partner notification (APN) is a voluntary and confidential process that utilizes specially-trained health workers to encourage and assist people diagnosed with HIV to inform their sex and drug use partners about possible shared exposure to HIV. With APN, partners who have come in contact with HIV are notified about exposure and given information to protect themselves from contracting HIV in the future or to begin treatment, if needed.\n\nThis study compares two types of HIV partner notification. Incarcerated men with HIV will be recruited as \"index participants\". Participants in both groups will be encouraged to notify sex and needle-sharing partners with whom they may have shared an HIV exposure before incarceration. All participants have the option to self-notify partners during a prison visitation or telephone call. In addition, participants randomized to an APN Choice group also can opt for anonymous notification by specially-trained APN notifiers that includes contact tracing if needed. As outcomes, we will compare the number of partners in each condition who are notified, HIV tested, diagnosed, and linked to HIV treatment. The study will show if prison-based APN is successful in reaching partners for HIV testing.",[566],"HIV",[566,568,569,570,571,572],"partner notification","contact tracing","sexually transmitted infections","prisons","Injection drug use",{"date":463,"type":32},{"date":575,"type":20},"2026-06",{"date":577,"type":20},"2028-12",{"name":38,"class":39},{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":585,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":16,"minAge":587,"maxAge":4,"enrollmentInfo":588,"targetDuration":4,"studyType":21,"phases":590,"briefSummary":591,"conditions":592,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":596,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":40},"100534628","executive-function-and-parenting-in-childhood-100534628","NCT06241300","Executive Function and Parenting in Childhood","Improving Brain-Behavior Markers of Preschool Executive Function Through a Group-Based Parenting Intervention for Low-Income Families","EPIC","Inclusion Criteria:\n\n* Children must be between the ages of 4 years old and 5 years, 11 months old\n* Parent must be the legal guardian of the target child and must live with the child full-time\n* Parents will be 18 years and older (no maximum age limit)\n* Only one child and one parent per family can participate in the study\n* Child is Medicaid eligible, defined as receiving Medicaid or eligible based on family income (up to 142 percent of the federal poverty level)\n* At enrollment the child will have moderate-to-severe (i.e., (sub)clinical) impairments in executive functioning as indicated by having a global executive composite standardized score greater than or equal to 60 on the Behavior Rating Inventory of Executive Function-Preschool Version (BRIEF-P), which will be completed by parents at the initial screen\n* Given that some assessment materials are only validated in English, parents and children for this study will need to be English-speaking\n* Child does not have a prior or current diagnosis of a disruptive behavior disorder based on Diagnostic Statistical Manual, Fifth Edition (DSM-5) criteria\n* Child is not currently receiving mental health services\n* Child does not take medications to treat emotional or behavioral problems\n* Child does not have a medical condition, such as epilepsy, that would interfere with the completion of study tasks\n* Child is not actively suicidal\n* Child does not have a history of psychosis or currently psychotic\n* Parent does not have a medical condition that would interfere with the completion of the study\n* Parent does not have an intellectual disability that would interfere with their ability to complete the study\n* Parent does not have a severe mental illness, active suicidal ideation, or current alcohol\u002Fsubstance abuse\u002Fdependence that would interfere with their ability to participate in the study\n* Child can have a current or past histories of psychiatric disorders (anxiety, mood, attention deficit hyperactivity disorder)\n* Parent can have current or past history of psychiatric disorders\n* Parent can be taking medications to treat mental health problems\n\nExclusion Criteria:\n\n* Child is not between the ages of 4-5 years old\n* The parent is not the legal guardian of the target child\n* The parent does not live with the child full-time\n* The parent is younger than 18 years old\n* Child is not receiving Medicaid or Medicaid eligible\n* Child does not have (sub)clinical impairments in executive functioning as indicated by having a global executive composite standardized score greater than or equal to 60 on the BRIEF\n* Child and parent are not English-Speaking\n* Child has a prior or current diagnosis of a disruptive behavior disorder based on DSM-5 criteria\n* Child is currently receiving mental health services\n* Child currently takes medications to treat emotional or behavioral problems\n* Child has a medical condition, such as epilepsy, that would interfere with the completion of study tasks\n* Child is actively suicidal\n* Child has a history of psychosis or is currently psychotic\n* Parent is not willing to be randomly assigned to receive the Chicago Parent Program intervention or to the control condition where they will not receive an intervention\n* Parent has a medical condition that would interfere with the completion of the study\n* Parent has an intellectual disability that would interfere with their ability to complete the study\n* Parent has a severe mental illness and\u002For active suicidal ideation","4 Years",{"count":589,"type":20},180,[76],"Deficits in executive functioning (EF) disproportionately impact children living in poverty and increase risk for psychopathology, particularly disruptive behavior disorders. This randomized clinical trial seeks to determine whether childhood EF, assessed across neural and behavioral units of analysis, is an experimental therapeutic target that can be directly modified through caregiver participation in the Chicago Parent Program (CPP), if increases in EF predict reduced disruptive behavior trajectories in low-income children over a short-term follow-up period, and identify which CPP-driven parenting skill improvements are the most influential in modifying EF. This work will contribute new knowledge as to whether a cost-efficient parenting intervention, developed for and with low-income families raising young children in poverty, can modify EF, a neural behavioral mechanism implicated in risk for childhood disruptive behavior problems.",[593,594,595],"Disruptive Behavior Disorder, Childhood Onset","Disruptive Behavior","Executive Function",{"date":463,"type":32},{"date":598,"type":32},"2023-11-20",{"date":600,"type":20},"2028-03-31",{"name":38,"class":39},{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":608,"eligibilityCriteria":609,"healthyVolunteers":12,"sex":400,"minAge":17,"maxAge":610,"enrollmentInfo":611,"targetDuration":4,"studyType":21,"phases":612,"briefSummary":613,"conditions":614,"keywords":626,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":628,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":116},"100457248","better-lifestyle-counseling-for-african-american-women-during-pregnancy-100457248","NCT05234125","Better Lifestyle Counseling for African American Women During Pregnancy","A Randomized Control Trial to Improve Metabolic Outcomes in African American Pregnant Women","BETTER","Inclusion Criteria:\n\n* African American pregnant woman.\n* Women between 16 and 22 GWs.\n* Overweight or obese - pregravid Body Mass Index \\>25.0 kg\u002Fm2.\n* Singleton gestation.\n* Established prenatal care at The University of Illinois Hospital \\& Health Sciences.\n* System Obstetric (UIHHSS' OB) clinics. Able to understand, speak and write in English.\n\nExclusion Criteria:\n\n* Multiple gestations.\n* Night-shift work.\n* Diagnosed sleep disorders.\n* Known fetal chromosomal or anatomical abnormalities.\n* Diagnosed mood disorders.\n* Gestational diabetes in early pregnancy.\n* Glycated Hemoglobin (HbA1c) ≥ 6.5%.\n* Hypoglycemic medications.\n* Stimulant medication or taking a sleeping aid.\n* Active drug abuse\u002Fexcessive alcohol intake.","40 Years",{"count":513,"type":20},[76],"The purpose of this randomized controlled trial is to establish the effectiveness of a culturally targeted and individually tailored behavioral intervention to promote maternal glucose metabolism in African American women.",[615,616,617,618,619,620,621,622,428,623,624,625],"Overweight or Obesity","Pregnancy Related","Sleep Disturbances","Sleep Hygiene","Pregnancy Complications","Diversity","Stress, Psychological","Fitness Trackers","African Americans","Disparities in Pregnancy Complications","Sleep Disparities",[627],"Sleep, Pregnancy, Intervention, glucose metabolism,",{"date":463,"type":32},{"date":630,"type":32},"2022-08-16",{"date":632,"type":20},"2027-12-30",{"name":38,"class":39},""]